- Home
- CCCM vs RGNX Comparison
CCCM vs RGNX Comparison
Compare CCCM & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCM
- RGNX
- Stock Information
- Founded
- CCCM 2024
- RGNX 2008
- Country
- CCCM United States
- RGNX United States
- Employees
- CCCM N/A
- RGNX N/A
- Industry
- CCCM Blank Checks
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCCM Finance
- RGNX Health Care
- Exchange
- CCCM Nasdaq
- RGNX Nasdaq
- Market Cap
- CCCM 353.0M
- RGNX 424.8M
- IPO Year
- CCCM 2025
- RGNX 2015
- Fundamental
- Price
- CCCM $10.30
- RGNX $9.12
- Analyst Decision
- CCCM
- RGNX Strong Buy
- Analyst Count
- CCCM 0
- RGNX 8
- Target Price
- CCCM N/A
- RGNX $31.75
- AVG Volume (30 Days)
- CCCM 20.1K
- RGNX 570.2K
- Earning Date
- CCCM 01-01-0001
- RGNX 08-08-2025
- Dividend Yield
- CCCM N/A
- RGNX N/A
- EPS Growth
- CCCM N/A
- RGNX N/A
- EPS
- CCCM N/A
- RGNX N/A
- Revenue
- CCCM N/A
- RGNX $156,718,000.00
- Revenue This Year
- CCCM N/A
- RGNX $327.08
- Revenue Next Year
- CCCM N/A
- RGNX N/A
- P/E Ratio
- CCCM N/A
- RGNX N/A
- Revenue Growth
- CCCM N/A
- RGNX 80.70
- 52 Week Low
- CCCM $10.08
- RGNX $5.04
- 52 Week High
- CCCM $17.00
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- CCCM N/A
- RGNX 45.87
- Support Level
- CCCM N/A
- RGNX $8.14
- Resistance Level
- CCCM N/A
- RGNX $9.22
- Average True Range (ATR)
- CCCM 0.00
- RGNX 0.50
- MACD
- CCCM 0.00
- RGNX 0.02
- Stochastic Oscillator
- CCCM 0.00
- RGNX 23.89
About CCCM Columbus Circle Capital Corp I Class A Ordinary Shares
Columbus Circle Capital Corp I is a blank check company.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.